• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Mass screening for neuroblastoma in Japan. Committee of the Neuroblastoma Mass Screening Study of the Japanese Society of Pediatric Oncology.

作者信息

Sawada T, Nagahara N, Yamamoto K, Okabe I, Hanawa Y, Hashizume K, Matsui I, Okawa H, Tsunoda A, Sakurai M

机构信息

Department of Pediatrics, Kyoto Prefectural University of Medicine, Japan.

出版信息

Acta Paediatr Jpn. 1990 Dec;32(6):725-33.

PMID:2082676
Abstract

The present status of NB mass screening in Japan, which is the first national trial in the world, is presented. This program was conducted in cooperation with infants' mothers, local health centers, screening centers and hospitals. Three hundred and thirty-seven cases detected by the program, from the start in Kyoto in 1974 to the end of 1989, are analyzed. As many cases were detected at early stages, 97% of them were expected to be cured. Several clinical, technical and programmatic problems are also discussed.

摘要

相似文献

1
Mass screening for neuroblastoma in Japan. Committee of the Neuroblastoma Mass Screening Study of the Japanese Society of Pediatric Oncology.
Acta Paediatr Jpn. 1990 Dec;32(6):725-33.
2
[Present status of neuroblastoma mass screening in Japan. Neuroblastoma-Committee of the Japanese Childhood Cancer Society].[日本神经母细胞瘤大规模筛查的现状。日本儿童癌症协会神经母细胞瘤委员会]
Gan To Kagaku Ryoho. 1990 Dec;17(12):2319-26.
3
Mass screening for neuroblastoma in Japan.日本的神经母细胞瘤大规模筛查。
Pediatr Hematol Oncol. 1991 Apr-Jun;8(2):93-109. doi: 10.3109/08880019109033437.
4
Past and future of neuroblastoma screening in Japan.日本神经母细胞瘤筛查的过去与未来。
Am J Pediatr Hematol Oncol. 1992 Nov;14(4):320-6.
5
The incidence and mortality rates of neuroblastoma cases before and after the cessation of the mass screening program in Japan: A descriptive study.日本大规模筛查计划停止前后神经母细胞瘤病例的发病率和死亡率:一项描述性研究。
Int J Cancer. 2017 Feb 1;140(3):618-625. doi: 10.1002/ijc.30482. Epub 2016 Nov 7.
6
Number and cure rate of neuroblastoma cases detected by the mass screening program in Japan: future aspects.日本大规模筛查项目检测出的神经母细胞瘤病例数量及治愈率:未来展望
Med Pediatr Oncol. 1987;15(1):14-7. doi: 10.1002/mpo.2950150104.
7
Analysis of 598 cases of neuroblastoma (NB) detected by screening and changes in the age distribution and incidence of NB patients after mass screening in infants in Japan. NB Screening Study Group.
Prog Clin Biol Res. 1994;385:371-5.
8
Stephen L. Gans overseas lecture. Mass screening for neuroblastoma in Japan: lessons learned and future directions.斯蒂芬·L·甘斯海外讲座。日本神经母细胞瘤的大规模筛查:经验教训与未来方向。
J Pediatr Surg. 2002 Jul;37(7):949-54. doi: 10.1053/jpsu.2002.33814.
9
Risks and benefits of ending of mass screening for neuroblastoma at 6 months of age in Japan.日本终止 6 月龄儿童神经母细胞瘤群体筛查的风险和获益。
J Pediatr Surg. 2009 Dec;44(12):2253-7. doi: 10.1016/j.jpedsurg.2009.07.050.
10
Effectiveness of screening for neuroblastoma at 6 months of age: a retrospective population-based cohort study.6个月大时神经母细胞瘤筛查的有效性:一项基于人群的回顾性队列研究。
Lancet. 2008 Apr 5;371(9619):1173-80. doi: 10.1016/S0140-6736(08)60523-1.

引用本文的文献

1
Serum-Based Quantification of MYCN Gene Amplification in Young Patients with Neuroblastoma: Potential Utility as a Surrogate Biomarker for Neuroblastoma.基于血清的儿童神经母细胞瘤患者MYCN基因扩增定量分析:作为神经母细胞瘤替代生物标志物的潜在用途
PLoS One. 2016 Aug 11;11(8):e0161039. doi: 10.1371/journal.pone.0161039. eCollection 2016.